<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494154</url>
  </required_header>
  <id_info>
    <org_study_id>IUCPQ-HDWOBPT</org_study_id>
    <nct_id>NCT02494154</nct_id>
  </id_info>
  <brief_title>Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Patients.</brief_title>
  <acronym>HDWOBPT</acronym>
  <official_title>Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the work of breathing among patients under various conditions of&#xD;
      treatment with high flow nasal cannulas. Sixteen spontaneously breathing patients with&#xD;
      respiratory failure (hypercapnic or hypoxemic) will be included. The design of this study is&#xD;
      a cross over of four treatment periods with different flow settings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High flow oxygen therapy (HFOT) is a promising technique increasingly used in the management&#xD;
      of acute respiratory failure. In hospitalised hypoxemic patients, recent clinical evidence&#xD;
      showed that HFOT can reduce endotracheal intubation and reduce mortality. Physiologically,&#xD;
      the HFOT causes a decrease in respiratory rate and minute-ventilation and may be associated&#xD;
      with a decrease in PaCO2. It is possible that these effects are associated with decreased&#xD;
      work of breathing, which could explain some of the benefits in terms of comfort and&#xD;
      efficiency.&#xD;
&#xD;
      The objective of this research is to evaluate the impact of a wash-out of anatomical dead&#xD;
      space by high flow nasal cannulas on respiratory parameters and on the work of breathing.&#xD;
&#xD;
      The investigators will evaluate the baseline status with conventional oxygen therapy methods&#xD;
      (low flows), and then compare it with three different levels of high flow oxygen therapy in a&#xD;
      randomised order. The primary endpoint will be the work of breathing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Work of breathing</measure>
    <time_frame>15 minutes</time_frame>
    <description>Work of breathing at the end of each period is calculated from the measurement of esophageal pressure and tidal volume (composite outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Esophageal pressure-time product</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measured at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tidal volume</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measured at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfort of breathing</measure>
    <time_frame>15 minutes</time_frame>
    <description>Subjective evaluation at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood gases</measure>
    <time_frame>15 minutes</time_frame>
    <description>Arterial or capillary blood gases at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>15 minutes</time_frame>
    <description>Evaluation on a borg scale at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measured at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measured at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-tidal carbon dioxide</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measured at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measured at the end of each period</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Conventional flow via nasal prongs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxygen delivery via conventional nasal interface with flow adjusted to reach a target SpO2 according to the patient's condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High flow nasal cannulas 20L/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxygen delivery via high flow nasal cannulas (20L/min) with fraction of inspired oxygen (FiO2) adjusted to reach a target SpO2 according to the patient's condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High flow nasal cannulas 40L/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxygen delivery via high flow nasal cannulas (40L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High flow nasal cannulas 60L/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxygen delivery via high flow nasal cannulas (60L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Airvo 2; Ficher and Paykel HealthCare</intervention_name>
    <description>High flow nasal cannulas</description>
    <arm_group_label>High flow nasal cannulas 20L/min</arm_group_label>
    <arm_group_label>High flow nasal cannulas 40L/min</arm_group_label>
    <arm_group_label>High flow nasal cannulas 60L/min</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oxygen delivery via conventional nasal mask</intervention_name>
    <description>Low flow of oxygen delivered through conventional nasal prongs</description>
    <arm_group_label>Conventional flow via nasal prongs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Spontaneously breathing patients exhibiting a respiratory distress defined by a respiratory&#xD;
        rate ≥ 20 breaths/min associated with&#xD;
&#xD;
          -  either hypoxemia (SpO2&lt;90% with O2≥3L/min) ;&#xD;
&#xD;
          -  or hypercapnia (PaCO2&gt;45 mmHg with a respiratory acidosis (pH&lt;7,38).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients below 18yo, pregnant or breastfeeding women;&#xD;
&#xD;
          -  Patients enrolled in another study excluding co-enrolment;&#xD;
&#xD;
          -  History of ear nose and throat disease (i.e. surgery, epistaxis, trauma), eso-gastric&#xD;
             disease (i.e. esophageal varices, digestive haemorrhage), rheumatologic or neurologic&#xD;
             disease possibly interfering with the design of the study;&#xD;
&#xD;
          -  Acute respiratory or cardiovascular disease contra-indicating the enrolment in the&#xD;
             study protocol (i.e. acute coronary syndrome, pulmonary embolism, pneumothorax);&#xD;
&#xD;
          -  Need for immediate intubation or for continuous noninvasive ventilation and/or recent&#xD;
             (&lt;6h) arterial blood gases showing a respiratory acidosis with a pH&lt;7.30;&#xD;
&#xD;
          -  Patient feeling nauseous or under recent fed condition (&lt;1h).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Lellouche, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Fondation IUCPQ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu Delorme, PT, MSc</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3508</phone_ext>
    <email>mathieu.delorme.2@ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François Lellouche, MD, PhD</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3298</phone_ext>
    <email>francois.lellouche@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IUCPQ</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Lellouche, MD, PhD</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3298</phone_ext>
      <email>francois.lellouche@criucpq.ulaval.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <last_update_submitted>July 9, 2015</last_update_submitted>
  <last_update_submitted_qc>July 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

